PredictImmune, in a joint initiative with the Crohn’s & Colitis Foundation, has announced the start of a jointly-sponsored study to validate PredictSURE IBD – the company’s first prognostic test for inflammatory bowel disease (IBD), in the US market.

The prognostic tools developer announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which will be a multi-centre, observational study of patients with active Crohn’s disease or ulcerative colitis, who are not receiving systemic steroids, immunomodulators or biologics.

The company stated that the study will recruit up to 200 patients from about 15 centres across the US, and that patients recruited by New York University/Bellevue are the first to join the study, which will continue to recruit. Patients’ progress will also be tracked up for up to 12 months following the initial blood sample collection.

Paul Kinnon, chief executive officer, PredictImmune said that he sees the partnership as a “positive step for both PredictImmune and IBD patients in the US”.

He continued, “It’s exciting to get the PRECIOUS study underway, enabling us to extend our validation cohort and reinforce the utility of the test in delivering insights into the long-term disease course of IBD patients at the point of diagnosis. The study takes both PredictImmune and the Crohn’s & Colitis Foundation a step closer to a common goal of improving disease outcomes and quality of life for patients with IBD in the US.”

PredictImmune has also just completed a £10 million fund raising and has successfully launched its first test for IBD globally; it will be providing its proprietary technology as both a laboratory service and as a kit depending on the needs of global markets requirements.